Status:

TERMINATED

Randomised Open Label Study of Insulin Degludec Versus Insulin Glargine U100 in Ramadan

Lead Sponsor:

Weill Cornell Medical College in Qatar

Collaborating Sponsors:

Novo Nordisk A/S

Conditions:

Type2 Diabetes

Eligibility:

All Genders

21-75 years

Phase:

PHASE4

Brief Summary

This is a study to be performed in Qatar that will look at the comparison of glycemic control in patients with type 2 diabetes on insulin glargine U100 with insulin degludec over the Ramadan period, t...

Detailed Description

This will be an open label randomised prospective study that will involve 280 insulin-treated patients with type 2 diabetes and who are receiving a basal insulin as part of their treatment regimen. Th...

Eligibility Criteria

Inclusion

  • Male subjects with type 2 diabetes between the age of 20-75 years who can speak and understand Arabic or English
  • Female subjects with type 2 diabetes between the age of 20-75 years who can speak and understand Arabic or English
  • Patients must be on any basal insulin (once daily)
  • Patients must be on any basal insulin (twice daily)
  • Patients on stable dose of oral antidiabetes drugs can be included (No change in the dose for the previous 12 weeks)
  • Body Mass Index \<40kg/m2
  • Subjects who have signed informed consent form
  • Patients will be fasting during Ramadan

Exclusion

  • Type 1 diabetes
  • Type 2 diabetes on a basal bolus regimen or those on premix insulin or on self-mix insulin
  • On GLP-1 receptor agonists medication
  • On glinide medication
  • Ischaemic heart disease
  • Left bundle branch block on ECG
  • Active diabetic retinopathy or maculopathy requiring acute treatment
  • Unwilling to follow the protocol
  • Pregnancy, intention to become pregnant, breastfeeding

Key Trial Info

Start Date :

January 7 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 31 2018

Estimated Enrollment :

273 Patients enrolled

Trial Details

Trial ID

NCT03349840

Start Date

January 7 2018

End Date

December 31 2018

Last Update

June 9 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hamad Medical Corporation

Doha, Qatar, 3050

Randomised Open Label Study of Insulin Degludec Versus Insulin Glargine U100 in Ramadan | DecenTrialz